

JosÃ© Luis Molinuevo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7413184/publications.pdf>

Version: 2024-02-01

276
papers

28,691
citations

15001

68
h-index

7043

159
g-index

289
all docs

289
docs citations

289
times ranked

26038
citing authors

#	ARTICLE	IF	CITATIONS
1	Description of a European memory clinic cohort undergoing amyloidâ€”PET: The AMYPAD Diagnostic and Patient Management Study. <i>Alzheimer's and Dementia</i> , 2023, 19, 844-856.	0.4	6
2	Genotypic effects of <i>APOE</i> ϵ 4 on resting-state connectivity in cognitively intact individuals support functional brain compensation. <i>Cerebral Cortex</i> , 2023, 33, 2748-2760.	1.6	5
3	Soundtrack of life: An fMRI study. <i>Behavioural Brain Research</i> , 2022, 418, 113634.	1.2	0
4	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
5	A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimerâ€™s Disease: Towards a More Continuous Approach. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 511-524.	1.2	5
6	Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium. <i>Alzheimer's and Dementia</i> , 2022, 18, 1957-1968.	0.4	2
7	Age, sex and <i>APOE</i> ϵ 4 modify the balance between soluble and fibrillar $A\beta$ -amyloid in non-demented individuals: topographical patterns across two independent cohorts. <i>Molecular Psychiatry</i> , 2022, 27, 2010-2018.	4.1	9
8	The protective gene dose effect of the <i>APOE</i> ϵ 2 allele on gray matter volume in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2022, 18, 1383-1395.	0.4	13
9	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.4	22
10	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of <i>Klotho</i> heterozygosity on disease risk. <i>PLoS ONE</i> , 2022, 17, e0267298.	1.1	9
11	Brain alterations in the early Alzheimerâ€™s continuum with amyloid- $A\beta$, tau, glial and neurodegeneration CSF markers. <i>Brain Communications</i> , 2022, 4, .	1.5	12
12	The Open-Access European Prevention of Alzheimerâ€™s Dementia (EPAD) MRI dataset and processing workflow. <i>NeuroImage: Clinical</i> , 2022, 35, 103106.	1.4	9
13	Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimerâ€™s continuum. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4567-4579.	3.3	16
14	Nonlinear interaction between <i>APOE</i> ϵ 4 allele load and age in the hippocampal surface of cognitively intact individuals. <i>Human Brain Mapping</i> , 2021, 42, 47-64.	1.9	12
15	Brain correlates of urban environmental exposures in cognitively unimpaired individuals at increased risk for Alzheimer's disease: A study on Barcelona's population. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12205.	1.2	7
16	Prevention of cognitive decline in subjective cognitive decline <i>APOE</i> ϵ 4 carriers after EGCG and a multimodal intervention (PENSA): Study design. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12155.	1.8	13
17	Effects of a Mindfulness-Based Intervention versus Health Self-Management on Subclinical Anxiety in Older Adults with Subjective Cognitive Decline: The SCD-Well Randomized Superiority Trial. <i>Psychotherapy and Psychosomatics</i> , 2021, 90, 341-350.	4.0	18
18	Subclinical Atherosclerosis and Brain Metabolism in Middle-Aged Individuals. <i>Journal of the American College of Cardiology</i> , 2021, 77, 888-898.	1.2	24

#	ARTICLE	IF	CITATIONS
19	Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2169-2182.	3.3	24
20	Effects of COVID-19 Home Confinement on Mental Health in Individuals with Increased Risk of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1015-1021.	1.2	8
21	Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 46.	3.0	9
22	Cerebral amyloid β load is associated with neurodegeneration and gliosis: Mediation by p τ and interactions with risk factors early in the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, 788-800.	0.4	14
23	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. <i>Alzheimer's and Dementia</i> , 2021, 17, 1575-1582.	0.4	51
24	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2183-2199.	3.3	16
25	Management and Quality Control of Large Neuroimaging Datasets: Developments From the Barcelona β Brain Research Center. <i>Frontiers in Neuroscience</i> , 2021, 15, 633438.	1.4	9
26	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, 1189-1204.	0.4	44
27	Accelerated long-term forgetting in individuals with subjective cognitive decline and amyloid β positivity. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1037-1049.	1.3	6
28	Genetic Influences on Hippocampal Subfields. <i>Neurology: Genetics</i> , 2021, 7, e591.	0.9	8
29	Genetic Predisposition to Alzheimer's Disease Is Associated with Enlargement of Perivascular Spaces in Centrum Semiovale Region. <i>Genes</i> , 2021, 12, 825.	1.0	7
30	Cognitively unimpaired individuals with a low burden of A β pathology have a distinct CSF biomarker profile. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 134.	3.0	8
31	Amyloid- β positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume. <i>Neurobiology of Aging</i> , 2021, 104, 24-31.	1.5	13
32	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021, 9, 36.	1.7	9
33	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's continuum. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 135.	3.0	30
34	Awareness of Cognitive Decline in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 697234.	1.7	17
35	Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 119-128.	1.2	3
36	CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET. <i>Neurology</i> , 2021, 97, e2065-e2078.	1.5	40

#	ARTICLE	IF	CITATIONS
37	Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. <i>Environment International</i> , 2021, 157, 106864.	4.8	40
38	Harmonisation and Between-Country Differences of the Lifetime of Experiences Questionnaire in Older Adults. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 740005.	1.7	4
39	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services" part 2 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 169.	3.0	35
40	Protocols for cognitive enhancement. A user manual for Brain Health Services" part 5 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 172.	3.0	15
41	Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services" part 4 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 171.	3.0	37
42	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021, 78, 1471.	4.5	204
43	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. <i>Biomedicine</i> , 2021, 9, 1610.	1.4	7
44	Self-reflection is associated with markers of Alzheimer's disease in cognitively unimpaired older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
45	Network analysis for studying the dynamics of affective symptoms and treatment adherence in APOE ϵ 4 carriers with subjective cognitive decline following a multimodal intervention: Preliminary findings from the PENSA Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
46	Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals. <i>Brain Imaging and Behavior</i> , 2020, 14, 2012-2023.	1.1	40
47	Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study. <i>Alzheimer's and Dementia</i> , 2020, 16, 292-304.	0.4	29
48	Association between insomnia and cognitive performance, gray matter volume, and white matter microstructure in cognitively unimpaired adults. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 4.	3.0	53
49	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 8.	3.0	12
50	CSF cutoffs for MCI due to AD depend on APOE ϵ 4 carrier status. <i>Neurobiology of Aging</i> , 2020, 89, 55-62.	1.5	11
51	Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , 2020, 95, e1538-e1553.	1.5	55
52	Sex Differences of Longitudinal Brain Changes in Cognitively Unimpaired Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1413-1422.	1.2	4
53	The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12021.	1.2	15
54	Association of years to parent's sporadic onset and risk factors with neural integrity and Alzheimer biomarkers. <i>Neurology</i> , 2020, 95, e2065-e2074.	1.5	3

#	ARTICLE	IF	CITATIONS
55	Effect of BDNF Val66Met on hippocampal subfields volumes and compensatory interaction with APOE-Îµ4 in middle-age cognitively unimpaired individuals from the ALFA study. <i>Brain Structure and Function</i> , 2020, 225, 2331-2345.	1.2	5
56	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimerâ€™s <i>continuum</i> when only subtle changes in AÎ² pathology are detected. <i>EMBO Molecular Medicine</i> , 2020, 12, e12921.	3.3	202
57	Operationalization of the ATN classification scheme in preclinical AD: Findings from EPAD V500.0 data release. <i>Alzheimer's and Dementia</i> , 2020, 16, e037912.	0.4	0
58	Use of the Medtep digital health platform in the framework of a multimodal intervention in patients with subjective cognitive decline (PENSA Study). <i>Alzheimer's and Dementia</i> , 2020, 16, e040447.	0.4	0
59	Examining centiloid quantification against visual assessment using [18F]flutemetamol PET. <i>Alzheimer's and Dementia</i> , 2020, 16, e042653.	0.4	0
60	Polygenic-wide analysis to assess the impact of genetic risk profiles on brain morphometry in the ALFA study. <i>Alzheimer's and Dementia</i> , 2020, 16, e042952.	0.4	0
61	Impact of the APOE gene on amyloid deposition in participants with abnormal soluble amyloid levels. <i>Alzheimer's and Dementia</i> , 2020, 16, e042955.	0.4	0
62	Subjective cognitive decline correlates with medial temporal lobe and hippocampal subfield volumetry in cognitively unimpaired participants. <i>Alzheimer's and Dementia</i> , 2020, 16, e043520.	0.4	0
63	Amyloid-Î², tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimerâ€™s continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044444.	0.4	0
64	Emerging beta-amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences. <i>Alzheimer's and Dementia</i> , 2020, 16, e044466.	0.4	1
65	Genetically predicted telomere length and Alzheimerâ€™s disease endophenotypes: A Mendelian randomization study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044720.	0.4	0
66	The effect of physical activity on CSF biomarkers of Alzheimerâ€™s disease differs between men and women. <i>Alzheimer's and Dementia</i> , 2020, 16, e044722.	0.4	0
67	Multiple biological pathways associate with cerebral amyloid load in the early Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044733.	0.4	0
68	Higher fronto-parietal metabolism parallels a greater impact of amyloid and anxiety on medial temporal areas in women versus men. <i>Alzheimer's and Dementia</i> , 2020, 16, e044780.	0.4	0
69	Multiple pathophysiological biomarkers are associated with gray matter volume and cerebral glucose metabolism in the early preclinical Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044808.	0.4	0
70	PENSA study: Study design, recruitment profiles and participant inclusion in multimodal intervention studies. <i>Alzheimer's and Dementia</i> , 2020, 16, e045074.	0.4	0
71	APOE -Îµ4 shapes temporo-parietal network properties in middle-aged, cognitively unimpaired individuals: A graph theory analysis. <i>Alzheimer's and Dementia</i> , 2020, 16, e045092.	0.4	0
72	Weight loss predicts Alzheimerâ€™s disease biomarker positivity in cognitively unimpaired middle-aged adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e045137.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Proximity to parental age at onset exacerbates amyloid burden while mental conditions exacerbate neural loss during midlife. <i>Alzheimer's and Dementia</i> , 2020, 16, e045171.	0.4	0
74	Between-country harmonization and differences of the Lifetime of Experiences Questionnaire (LEQ) for lifespan complex mental activity assessment. <i>Alzheimer's and Dementia</i> , 2020, 16, e045240.	0.4	1
75	Incidence of subjective cognitive decline is associated with amyloid β^2 pathology, whereas stability relates to neurodegeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, e045293.	0.4	0
76	Harmonization of amyloid PET scans minimizes the impact of reconstruction parameters on centiloid values. <i>Alzheimer's and Dementia</i> , 2020, 16, e045294.	0.4	2
77	Amyloid β -positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to hippocampal volume. <i>Alzheimer's and Dementia</i> , 2020, 16, e045715.	0.4	0
78	The Barcelona dementia prevention research clinic: Study design, recruitment profiles and inclusion in prevention studies – An update. <i>Alzheimer's and Dementia</i> , 2020, 16, e045800.	0.4	0
79	Impact of APOE ϵ^4 on cerebral amyloid deposition in participants with abnormal soluble amyloid levels. <i>Alzheimer's and Dementia</i> , 2020, 16, e045828.	0.4	1
80	ALFA+: A cohort study to understand and model the preclinical stage of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045935.	0.4	0
81	Quantitative informant and self-reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE ϵ^4 . <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12127.	1.2	6
82	Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, 1358-1371.	0.4	120
83	APOE- ϵ^4 Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks. <i>Cerebral Cortex</i> , 2020, 30, 4110-4120.	1.6	7
84	NeAT: a Nonlinear Analysis Toolbox for Neuroimaging. <i>Neuroinformatics</i> , 2020, 18, 517-530.	1.5	0
85	Impact of urban environmental exposures on cognitive performance and brain structure of healthy individuals at risk for Alzheimer's dementia. <i>Environment International</i> , 2020, 138, 105546.	4.8	69
86	The relation between APOE genotype and cerebral microbleeds in cognitively unimpaired middle- and old-aged individuals. <i>Neurobiology of Aging</i> , 2020, 95, 104-114.	1.5	15
87	The characterisation of subjective cognitive decline. <i>Lancet Neurology</i> , The, 2020, 19, 271-278.	4.9	627
88	Dementia care during COVID-19. <i>Lancet</i> , The, 2020, 395, 1190-1191.	6.3	412
89	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2020, 16, 750-758.	0.4	29
90	Microglial Hyperreactivity Evolved to Immunosuppression in the Hippocampus of a Mouse Model of Accelerated Aging and Alzheimer's Disease Traits. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 622360.	1.7	9

#	ARTICLE	IF	CITATIONS
91	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020, 143, 3776-3792.	3.7	89
92	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18 F]flutemetamol PET images. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.4	0
93	A creation approach to design the implementation of a multimodal intervention in patients with subjective cognitive decline (PENSA study). <i>Alzheimer's and Dementia</i> , 2020, 16, e042998.	0.4	0
94	Predicting and Tracking Short Term Disease Progression in Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 3-14.	1.2	18
95	Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 72.	3.0	23
96	The <i>MS4A</i> gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	170
97	Associations Between the Subjective Cognitive Decline-Questionnaire Scores, Gray Matter Volume, and Amyloid- β Levels. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 1287-1302.	1.2	6
98	Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 74.	3.0	28
99	Interactive effect of age and APOE- ϵ 4 allele load on white matter myelin content in cognitively normal middle-aged subjects. <i>NeuroImage: Clinical</i> , 2019, 24, 101983.	1.4	30
100	Spatial patterns of white matter hyperintensities associated with Alzheimer's disease risk factors in a cognitively healthy middle-aged cohort. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 12.	3.0	46
101	Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 8.	3.0	23
102	Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for Stakeholders. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 323-341.	1.2	146
103	Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 164-174.	1.8	30
104	APOE- ϵ 4 risk variant for Alzheimer's disease modifies the association between cognitive performance and cerebral morphology in healthy middle-aged individuals. <i>NeuroImage: Clinical</i> , 2019, 23, 101818.	1.4	18
105	Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 33.	3.0	30
106	Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 27.	3.0	82
107	Is there a difference in regional read [18F]flutemetamol amyloid patterns between end-of-life subjects and those with amnesic mild cognitive impairment?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1299-1308.	3.3	10
108	Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 22, 101777.	1.4	29

#	ARTICLE	IF	CITATIONS
109	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753.	0.4	82
110	CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. <i>NeuroImage: Clinical</i> , 2019, 23, 101801.	1.4	26
111	Biomarker Matrix to Track Short Term Disease Progression in Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 49-58.	1.2	8
112	ICâ€²02â€²05: GENDER DIFFERENCES IN THE ASSOCIATION BETWEEN LONGITUDINAL BRAIN CHANGES AND BASELINE LEVELS OF CSF ALZHEIMER'S DISEASE AND GLIAL BIOMARKERS IN HEALTHY ELDERLY. <i>Alzheimer's and Dementia</i> , 2019, 15, P4.	0.4	0
113	Physical activity is associated with better global cognition and frontal function in overweight/obese older adults with metabolic syndrome. <i>European Review of Aging and Physical Activity</i> , 2019, 16, 23.	1.3	13
114	Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641988881.	1.5	46
115	Plasma AÎ²42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnesic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 37-48.	1.2	23
116	Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2019, 15, 465-476.	0.4	232
117	Two-Year Longitudinal Monitoring of Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 15-35.	1.2	34
118	Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 303-313.	1.2	8
119	AMYPAD Diagnostic and Patient Management Study: Rationale and design. <i>Alzheimer's and Dementia</i> , 2019, 15, 388-399.	0.4	37
120	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's diseaseâ€”Data from three memory clinic studies. <i>Alzheimer's and Dementia</i> , 2019, 15, 185-193.	0.4	28
121	Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. <i>NeuroImage: Clinical</i> , 2018, 19, 190-201.	1.4	16
122	Wishes and preferences for an online lifestyle program for brain healthâ€”A mixed methods study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 141-149.	1.8	11
123	NIAâ€”AA Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 535-562.	0.4	5,861
124	The Rationale Behind the New Alzheimer's Disease Conceptualization: Lessons Learned During the Last Decades. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1067-1077.	1.2	19
125	Long-term exposure to residential green and blue spaces and anxiety and depression in adults: A cross-sectional study. <i>Environmental Research</i> , 2018, 162, 231-239.	3.7	208
126	Structural Connectivity Alterations Along the Alzheimer's Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid-Î² and Tau. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1575-1587.	1.2	25

#	ARTICLE	IF	CITATIONS
127	Learning non-linear patch embeddings with neural networks for label fusion. <i>Medical Image Analysis</i> , 2018, 44, 143-155.	7.0	21
128	Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 130.	3.8	121
129	Tauopathy with Hippocampal 4â€Repeat Tau Immunoreactive Spherical Inclusions in a Patient with PSP. <i>Brain Pathology</i> , 2018, 28, 284-286.	2.1	4
130	European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. <i>Alzheimer's and Dementia</i> , 2018, 14, 837-842.	0.4	20
131	Effects of <i>APOE</i> ϵ 4 allele load on brain morphology in a cohort of middle-aged healthy individuals with enriched genetic risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 902-912.	0.4	98
132	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.4	58
133	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	1.3	215
134	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	6.0	133
135	P2â€262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM. <i>Alzheimer's and Dementia</i> , 2018, 14, P777.	0.4	0
136	Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 123.	3.0	73
137	The SCDâ€Well randomized controlled trial: Effects of a mindfulness-based intervention versus health education on mental health in patients with subjective cognitive decline (SCD). <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 737-745.	1.8	26
138	Computer-assisted prediction of clinical progression in the earliest stages of AD. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 726-736.	1.2	8
139	European Prevention of Alzheimerâ€™s Dementia Longitudinal Cohort Study (EPAD LCS): study protocol. <i>BMJ Open</i> , 2018, 8, e021017.	0.8	72
140	Current state of Alzheimerâ€™s fluid biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 821-853.	3.9	370
141	Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimerâ€™s disease clinical program. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 116.	3.0	28
142	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 100.	3.0	64
143	Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1505-1521.	0.4	163
144	Secondary prevention of Alzheimerâ€™s dementia: neuroimaging contributions. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 112.	3.0	46

#	ARTICLE	IF	CITATIONS
145	P2â€458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIFâ€AD BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P895.	0.4	0
146	Episodic memory and executive functions in cognitively healthy individuals display distinct neuroanatomical correlates which are differentially modulated by aging. <i>Human Brain Mapping</i> , 2018, 39, 4565-4579.	1.9	32
147	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , 2018, 14, 1313-1333.	0.4	87
148	Distinct Cognitive and Brain Morphological Features in Healthy Subjects Unaware of Informant-Reported Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 181-191.	1.2	15
149	MRI-Based Screening of Preclinical Alzheimerâ€™s Disease for Prevention Clinical Trials. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1099-1112.	1.2	18
150	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 64.	3.0	62
151	White matter microstructure is altered in cognitively normal middle-aged APOE-Î¼4 homozygotes. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 48.	3.0	43
152	Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies. <i>Methods in Molecular Biology</i> , 2018, 1750, 165-184.	0.4	0
153	The <i>APOE</i> Î¼4 genotype modulates CSF YKLâ€40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 50-59.	1.2	36
154	The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study. <i>Alzheimer's and Dementia</i> , 2017, 13, 1013-1023.	0.4	33
155	Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnesic mild cognitive impairment (MCI). <i>Neurobiology of Aging</i> , 2017, 53, 1-10.	1.5	59
156	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomalâ€dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 1251-1260.	0.4	47
157	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	1.2	197
158	Incidental findings on brain MRI of cognitively normal first-degree descendants of patients with Alzheimer's disease: a cross-sectional analysis from the ALFA (Alzheimer and Families) project. <i>BMJ Open</i> , 2017, 7, e013215.	0.8	28
159	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 274-284.	0.4	113
160	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2017, 13, 285-295.	0.4	108
161	Alzheimerâ€™s disease prevention: from risk factors to early intervention. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 71.	3.0	424
162	Cost-Utility of Using Alzheimerâ€™s Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1477-1487.	1.2	31

#	ARTICLE	IF	CITATIONS
163	Frontotemporal Dementia Caused by the P301L Mutation in <i>MAPT</i> ; Gene: Clinicopathological Features of 13 Cases from the Same Geographical Origin in Barcelona, Spain. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 44, 213-221.	0.7	31
164	A whole-brain computational modeling approach to explain the alterations in resting-state functional connectivity during progression of Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2017, 16, 343-354.	1.4	73
165	Effect of long-term exposure to air pollution on anxiety and depression in adults: A cross-sectional study. <i>International Journal of Hygiene and Environmental Health</i> , 2017, 220, 1074-1080.	2.1	161
166	CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study. <i>Molecular Neurobiology</i> , 2017, 54, 6647-6654.	1.9	45
167	Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations. <i>Molecular Neurobiology</i> , 2017, 54, 5550-5562.	1.9	119
168	[P2355]: CSF STREMLIN2, BUT NOT YKL40, IS ASSOCIATED WITH LONGITUDINAL MORPHOLOGICAL BRAIN CHANGES IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P758.	0.4	0
169	[P1058]: RESPONDER ANALYSIS OF THE COGNITIVE EFFECT OF COMBINATION THERAPY WITH DONEPEZIL AND INTELON (RVT101) VERSUS DONEPEZIL MONOTHERAPY: RESULTS FROM A 48-WEEK MULTINATIONAL PLACEBO-CONTROLLED STUDY IN MILD TO MODERATE ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P259.	0.4	2
170	[P3566]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1195.	0.4	0
171	[P4157]: CSF BIOMARKERS AND EFFECT OF APOLIPOPROTEIN E GENOTYPE, AGE AND SEX ON CUT-OFF DERIVATION IN MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1319.	0.4	4
172	[P4214]: TOWARD A FUNCTIONAL NEUROMARKER FOR PRECLINICAL AD: EIGENVECTOR CENTRALITY REVEALS PRECLINICAL DIFFERENCES OF FUNCTIONAL INFORMATION FLOW IN THE HIPPOCAMPUS, PRECUNEUS, CEREBELLUM AND INFERIOR PARIETAL LOBULE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1348.	0.4	0
173	[P4377]: EXPECTATIONS RELATED TO THE IMPLICATIONS OF LEARNING ALZHEIMER'S DISEASE RISK AMONG COGNITIVELY HEALTHY RESEARCH PARTICIPANTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1437.	0.4	0
174	[TD020]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, P166.	0.4	0
175	[P1289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF A β 2 OR AMYLOID-PET) IN THE EMIFAD BIOMARKER DISCOVERY COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P361.	0.4	0
176	[P2212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER'S DISEASE (EMIFAD): THE BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P691.	0.4	1
177	[O1103]: CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P218.	0.4	0
178	Executive and Language Subjective Cognitive Decline Complaints Discriminate Preclinical Alzheimer's Disease from Normal Aging. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 689-703.	1.2	33
179	Exome sequencing in a consanguineous family clinically diagnosed with early-onset Alzheimer's disease identifies a homozygous CTSF mutation. <i>Neurobiology of Aging</i> , 2016, 46, 236.e1-236.e6.	1.5	34
180	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 159-170.	1.2	23

#	ARTICLE	IF	CITATIONS
181	Cerebrospinal Fluid AÎ²42/40 Corresponds Better than AÎ²42 to Amyloid PET in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 813-822.	1.2	191
182	Quantitative Magnetic Resonance Abnormalities in Creutzfeldt-Jakob Disease and Fatal Insomnia. Journal of Alzheimer's Disease, 2016, 55, 431-443.	1.2	17
183	White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 827-835.	1.2	17
184	P2-302: CSF Beta-Amyloid- and APOE Îµ4-Related Decline in Episodic Memory Over 12 Months Measured using the Cantab in Individuals with Amnesic MCI: Results from the European ADNI Study. , 2016, 12, P751-P751.		2
185	P3Îµ15: Differential Effects of Apoe and CSF Amyloid on Memory Impairment in Individuals with Amnesic MCI Using the Cantab Cognitive Battery: Results from the Europeanâ€Adni Study. Alzheimer's and Dementia, 2016, 12, P964.	0.4	1
186	The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 82-92.	1.8	97
187	Modeling practice effects in healthy middleâ€aged participants of the Alzheimer and Families parent cohort. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 149-158.	1.2	6
188	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	1.2	18
189	Preservation of cell-survival mechanisms by the presenilin-1 K239N mutation may cause its milder clinical phenotype. Neurobiology of Aging, 2016, 46, 169-179.	1.5	5
190	Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1259-1272.	0.4	86
191	P2Îµ35: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples. Alzheimer's and Dementia, 2016, 12, P770.	0.4	0
192	Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. Neurodegenerative Diseases, 2016, 16, 69-76.	0.8	36
193	CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Neurobiology of Aging, 2016, 38, 47-55.	1.5	54
194	Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. Lancet Psychiatry,the, 2016, 3, 179-186.	3.7	171
195	Altered Blood Gene Expression of Tumor-Related Genes (PRKCB, BECN1, and CDKN2A) in Alzheimerâ€™s Disease. Molecular Neurobiology, 2016, 53, 5902-5911.	1.9	15
196	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease, 2015, 48, S63-S86.	1.2	317
197	Informantsâ€™ Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimerâ€™s Disease from Normalâ€Aging. Journal of Alzheimer's Disease, 2015, 48, S87-S98.	1.2	50
198	Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimerâ€™s dementia: a pooled area under the curve analysis. Alzheimer's Research and Therapy, 2015, 7, 28.	3.0	57

#	ARTICLE	IF	CITATIONS
199	Diagnostic accuracy of behavioral variant frontotemporal dementia consortium criteria (FTDC) in a clinicopathological cohort. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 882-892.	1.8	26
200	Evolving brain structural changes in PSEN1 mutation carriers. <i>Neurobiology of Aging</i> , 2015, 36, 1261-1270.	1.5	30
201	Correlates of cerebrospinal fluid levels of oligomeric- and total- α -synuclein in premotor, motor and dementia stages of Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 294-306.	1.8	85
202	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	3.8	1,166
203	Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: consensus proposal from the SEMNIM and SEN. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2015, 34, 303-313.	0.1	3
204	Recomendaciones para la utilización de biomarcadores de imagen PET en el proceso diagnóstico de las enfermedades neurodegenerativas que cursan con demencia: documento de consenso SEMNIM y SEN. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2015, 34, 303-313.	0.0	16
205	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015, 11, 41-55.	4.9	144
206	Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 455-461.	0.4	9
207	Usefulness of Biomarkers in the Diagnosis and Prognosis of Early-Onset Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 919-927.	1.2	32
208	Measuring decline in prodromal AD: a pike to hike. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 358-358.	0.9	1
209	Spanish Multicenter Normative Studies (NEURONORMA Project): Normative Data and Equivalence of Four BNT Short-Form Versions. <i>Archives of Clinical Neuropsychology</i> , 2014, 29, 60-74.	0.3	13
210	Determination of Neuronal Antibodies in Suspected and Definite Creutzfeldt-Jakob Disease. <i>JAMA Neurology</i> , 2014, 71, 74.	4.5	59
211	Reply. <i>Annals of Neurology</i> , 2014, 75, 460-461.	2.8	0
212	Identification of blood serum microRNAs associated with idiopathic and <i>LRRK2</i> Parkinson's disease. <i>Journal of Neuroscience Research</i> , 2014, 92, 1071-1077.	1.3	122
213	Neuropathology of prodromal Lewy body disease. <i>Movement Disorders</i> , 2014, 29, 410-415.	2.2	71
214	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 844-852.	0.4	1,863
215	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , 2014, 13, 614-629.	4.9	2,657
216	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 684-691.	0.9	55

#	ARTICLE	IF	CITATIONS
217	Cerebrospinal Fluid Level of YKL-40 Protein in Preclinical and Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 901-908.	1.2	102
218	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2014, 10, 808-817.	0.4	163
219	Cost-Effectiveness of the Use of Biomarkers in Cerebrospinal Fluid for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 777-788.	1.2	32
220	White matter changes in preclinical Alzheimer's disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid β^2 protein 42 levels. <i>Neurobiology of Aging</i> , 2014, 35, 2671-2680.	1.5	72
221	Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2014, 29, 1774-1780.	2.2	74
222	Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. <i>PLoS ONE</i> , 2014, 9, e89741.	1.1	407
223	Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2013, 74, 655-668.	2.8	171
224	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013, 9, 251-261.	0.4	344
225	A preliminary study of the whole-genome expression profile of sporadic and monogenic early-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 1772-1778.	1.5	87
226	Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 443-453.	4.9	602
227	Donepezil Treatment Stabilizes Functional Connectivity During Resting State and Brain Activity During Memory Encoding in Alzheimer's Disease. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 199-205.	0.7	40
228	Clinical Observational Research on Alzheimer's Disease: What Clinical Trial Registries Can Tell. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 183-190.	1.2	2
229	Evolving Brain Functional Abnormalities in PSEN1 Mutation Carriers: A Resting and Visual Encoding fMRI Study. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 165-175.	1.2	19
230	Identifying Earlier Alzheimer's Disease: Insights from the Preclinical and Prodromal Phases. <i>Neurodegenerative Diseases</i> , 2012, 10, 158-160.	0.8	12
231	The amyloid- β^2 isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease. <i>Molecular Medicine Reports</i> , 2012, 5, 1111-1115.	1.1	17
232	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2012, 8, 65-73.	0.4	271
233	Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 31-37.	1.4	32
234	Serum Progranulin Levels in Patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease: Detection of GRN Mutations in a Spanish Cohort. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 581-591.	1.2	31

#	ARTICLE	IF	CITATIONS
235	Using artificial neural networks in clinical neuropsychology: High performance in mild cognitive impairment and Alzheimer's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 195-208.	0.8	39
236	Multiple DTI index analysis in normal aging, amnesic MCI and AD. Relationship with neuropsychological performance. <i>Neurobiology of Aging</i> , 2012, 33, 61-74.	1.5	241
237	Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 127-134.	1.3	38
238	APOE Status Modulates the Changes in Network Connectivity Induced by Brain Stimulation in Non-Demented Elders. <i>PLoS ONE</i> , 2012, 7, e51833.	1.1	34
239	Specific Anatomic Associations Between White Matter Integrity and Cognitive Reserve in Normal and Cognitively Impaired Elders. <i>American Journal of Geriatric Psychiatry</i> , 2011, 19, 33-42.	0.6	36
240	A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease. <i>Neuroscience Letters</i> , 2011, 496, 40-42.	1.0	13
241	Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy. <i>Journal of Hepatology</i> , 2011, 55, 564-573.	1.8	96
242	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2011, 7, 386.	0.4	354
243	Cerebrospinal Fluid Biomarkers and Memory Present Distinct Associations along the Continuum from Healthy Subjects to AD Patients. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 319-326.	1.2	66
244	Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. <i>Psychiatry Research - Neuroimaging</i> , 2011, 192, 140-146.	0.9	19
245	Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. <i>Lancet Neurology</i> , The, 2011, 10, 797-805.	4.9	293
246	Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. <i>Journal of Neural Transmission</i> , 2011, 118, 259-262.	1.4	49
247	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease Families with PSEN1 Mutations. <i>Neurodegenerative Diseases</i> , 2011, 8, 202-207.	0.8	24
248	Spanish Multicenter Normative Studies (Neuronorma Project): Norms for the Abbreviated Barcelona Test. <i>Archives of Clinical Neuropsychology</i> , 2011, 26, 144-157.	0.3	36
249	Clinical, Neuropathologic, and Biochemical Profile of the Amyloid Precursor Protein I716F Mutation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 53-59.	0.9	52
250	Increased Cortical Thickness and Caudate Volume Precede Atrophy in PSEN1 Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 909-922.	1.2	136
251	Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. <i>Lancet Neurology</i> , The, 2010, 9, 1070-1077.	4.9	349
252	Cognitive reserve modulates task-induced activations and deactivations in healthy elders, amnesic mild cognitive impairment and mild Alzheimer's disease. <i>Cortex</i> , 2010, 46, 451-461.	1.1	136

#	ARTICLE	IF	CITATIONS
253	Electroencephalographic slowing heralds mild cognitive impairment in idiopathic REM sleep behavior disorder. <i>Sleep Medicine</i> , 2010, 11, 534-539.	0.8	97
254	Spanish Multicenter Normative Studies (NEURONORMA Project): Methods and Sample Characteristics. <i>Archives of Clinical Neuropsychology</i> , 2009, 24, 307-319.	0.3	206
255	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for the Visual Object and Space Perception Battery-Abbreviated, and Judgment of Line Orientation. <i>Archives of Clinical Neuropsychology</i> , 2009, 24, 355-370.	0.3	32
256	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for Verbal Fluency Tests. <i>Archives of Clinical Neuropsychology</i> , 2009, 24, 395-411.	0.3	201
257	Interactions of cognitive reserve with regional brain anatomy and brain function during a working memory task in healthy elders. <i>Biological Psychology</i> , 2009, 80, 256-259.	1.1	81
258	Brain structure and function related to cognitive reserve variables in normal aging, mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009, 30, 1114-1124.	1.5	315
259	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for the Stroop Color-Word Interference Test and the Tower of London-Drexel. <i>Archives of Clinical Neuropsychology</i> , 2009, 24, 413-429.	0.3	75
260	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for Verbal Span, Visuospatial Span, Letter and Number Sequencing, Trail Making Test, and Symbol Digit Modalities Test. <i>Archives of Clinical Neuropsychology</i> , 2009, 24, 321-341.	0.3	149
261	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for the Rey-Osterrieth Complex Figure (Copy and Memory), and Free and Cued Selective Reminding Test. <i>Archives of Clinical Neuropsychology</i> , 2009, 24, 371-393.	0.3	133
262	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for Boston Naming Test and Token Test. <i>Archives of Clinical Neuropsychology</i> , 2009, 24, 343-354.	0.3	74
263	Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration. <i>Journal of Neurology</i> , 2008, 255, 488-494.	1.8	40
264	Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. <i>Journal of the Neurological Sciences</i> , 2008, 270, 94-98.	0.3	35
265	Normative data for the Boston Naming Test and the Pyramids and Palm Trees Test in the elderly Spanish population. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2008, 30, 1-6.	0.8	45
266	First demonstrated de novo insertion in the prion protein gene in a young patient with dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 845-846.	0.9	11
267	Clinical and Pathological Heterogeneity of Neuronal Intermediate Filament Inclusion Disease. <i>Archives of Neurology</i> , 2008, 65, 272-5.	4.9	27
268	Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. <i>Lancet Neurology</i> , The, 2006, 5, 572-577.	4.9	901
269	Repetitive Transcranial Magnetic Stimulation Effects on Brain Function and Cognition among Elders with Memory Dysfunction. A Randomized Sham-Controlled Study. <i>Cerebral Cortex</i> , 2006, 16, 1487-1493.	1.6	169
270	A Novel Mutation in the PSEN2 Gene (T430M) Associated With Variable Expression in a Family With Early-Onset Alzheimer Disease. <i>Archives of Neurology</i> , 2003, 60, 1149.	4.9	46

#	ARTICLE	IF	CITATIONS
271	Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 372-377.	2.2	148
272	Further extension of the H1 haplotype associated with progressive supranuclear palsy. <i>Movement Disorders</i> , 2002, 17, 550-556.	2.2	61
273	Prepulse modulation of the startle reaction and the blink reflex in normal human subjects. <i>Experimental Brain Research</i> , 1999, 129, 49-56.	0.7	79
274	Identification of a novel polymorphism in the promoter region of the tau gene highly associated to progressive supranuclear palsy in humans. <i>Neuroscience Letters</i> , 1999, 275, 183-186.	1.0	56
275	Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. <i>Annals of Neurology</i> , 1998, 44, 976-980.	2.8	140
276	Significant Changes in the Tau A0 and A3 Alleles in Progressive Supranuclear Palsy and Improved Genotyping by Silver Detection. <i>Archives of Neurology</i> , 1998, 55, 1122.	4.9	85